File Download

There are no files associated with this item.

Supplementary

Conference Paper: Impact of Graft Type on the Survival Outcome of Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma

TitleImpact of Graft Type on the Survival Outcome of Salvage Liver Transplantation for Recurrent Hepatocellular Carcinoma
Authors
Issue Date2014
PublisherInternational Liver Transplantation Society (ILTS).
Citation
The Joint International Congress of International Liver Transplantation Society (ILTS), European Liver and Intestine Transplant Association (ELITA) and Liver Intensive Care Group of Europe (LICAGE), London, United Kingdom, 4-7 June 2014, p. abstract no. P-677 How to Cite?
AbstractAim: To evaluate the prognostic influence of graft type on salvage liver transplantation (SLT) for recurrent hepatocellular carcinoma (HCC) Methods: A retrospective analysis of 31 patients who underwent SLT for tumor recurrence after primary surgical treatment for HCC between year 2000-2011 was conducted. All the primary tumors were within USCF criteria. Survival analysis was conducted by Kaplan-Meier methods and compared between groups by log-rank test. P-value < 0.05 was considered significant. Results: A total of 22 patients received living-related SLT (LDSLT) and the remaining 9 patients received cadaveric-related SLT (DDSLT). 10 patients (LDSLT: n=7; DDSLT: n=3) underwent hepatectomy and 21 patients (LDSLT: n=15, DDSLT: n= 6) received radiofrequency ablation as primary treatment for HCC prior to SLT. 11 patients (LDSLT:n=9 vs. DDSLT:n=2, p=0.324) underwent SLT for recurrence beyond the UCSF criteria. 5 patients in each group received TACE as bridging treatment. LDSLT patients were significantly younger (age 53 vs. 58, p=0.046)) and had higher AFP levels (187.1 vs. 30.5ng/ml, p = 0.006) at first diagnosis of HCC than DDSLT patients. There was no significant difference with regard to primary tumor size (2.5 vs. 2.5cm), time to recurrence after primary treatment (15 vs. 8 months), recurrent tumor size (4.0 vs. 4.0cm) and number (n=2 vs. 2), and serum AFP level at recurrence (27.5 vs. 5.0ng/ml) between the two groups. The 1-, 3- and 5-year recurrence-free survival rates for LDSLT were 81.8%, 61.4% and 61.4%; and the corresponding survival rates for DDSLT were all 88.9% (p = 0.176). Conclusion Our study showed that both LDSLT and DDSLT attained satisfactory long-term survival benefit. Although statistically insignificant, DDSLT appeared to have a more favorable oncological outcome than LDSLT. Further studies with larger cohort are warranted to elucidate this issue.
DescriptionPoster Session III
The abstract can be viewed at: http://www.abstracts2view.com/ilts/view.php?nu=ILTS14L1_P-677
Persistent Identifierhttp://hdl.handle.net/10722/198643

 

DC FieldValueLanguage
dc.contributor.authorChan, ACYen_US
dc.contributor.authorChan, SCen_US
dc.contributor.authorChok, KSHen_US
dc.contributor.authorCheung, TTen_US
dc.contributor.authorLo, CMen_US
dc.date.accessioned2014-07-07T08:29:35Z-
dc.date.available2014-07-07T08:29:35Z-
dc.date.issued2014en_US
dc.identifier.citationThe Joint International Congress of International Liver Transplantation Society (ILTS), European Liver and Intestine Transplant Association (ELITA) and Liver Intensive Care Group of Europe (LICAGE), London, United Kingdom, 4-7 June 2014, p. abstract no. P-677en_US
dc.identifier.urihttp://hdl.handle.net/10722/198643-
dc.descriptionPoster Session III-
dc.descriptionThe abstract can be viewed at: http://www.abstracts2view.com/ilts/view.php?nu=ILTS14L1_P-677-
dc.description.abstractAim: To evaluate the prognostic influence of graft type on salvage liver transplantation (SLT) for recurrent hepatocellular carcinoma (HCC) Methods: A retrospective analysis of 31 patients who underwent SLT for tumor recurrence after primary surgical treatment for HCC between year 2000-2011 was conducted. All the primary tumors were within USCF criteria. Survival analysis was conducted by Kaplan-Meier methods and compared between groups by log-rank test. P-value < 0.05 was considered significant. Results: A total of 22 patients received living-related SLT (LDSLT) and the remaining 9 patients received cadaveric-related SLT (DDSLT). 10 patients (LDSLT: n=7; DDSLT: n=3) underwent hepatectomy and 21 patients (LDSLT: n=15, DDSLT: n= 6) received radiofrequency ablation as primary treatment for HCC prior to SLT. 11 patients (LDSLT:n=9 vs. DDSLT:n=2, p=0.324) underwent SLT for recurrence beyond the UCSF criteria. 5 patients in each group received TACE as bridging treatment. LDSLT patients were significantly younger (age 53 vs. 58, p=0.046)) and had higher AFP levels (187.1 vs. 30.5ng/ml, p = 0.006) at first diagnosis of HCC than DDSLT patients. There was no significant difference with regard to primary tumor size (2.5 vs. 2.5cm), time to recurrence after primary treatment (15 vs. 8 months), recurrent tumor size (4.0 vs. 4.0cm) and number (n=2 vs. 2), and serum AFP level at recurrence (27.5 vs. 5.0ng/ml) between the two groups. The 1-, 3- and 5-year recurrence-free survival rates for LDSLT were 81.8%, 61.4% and 61.4%; and the corresponding survival rates for DDSLT were all 88.9% (p = 0.176). Conclusion Our study showed that both LDSLT and DDSLT attained satisfactory long-term survival benefit. Although statistically insignificant, DDSLT appeared to have a more favorable oncological outcome than LDSLT. Further studies with larger cohort are warranted to elucidate this issue.-
dc.languageengen_US
dc.publisherInternational Liver Transplantation Society (ILTS).-
dc.relation.ispartofJoint International Congress of International Liver Transplantation Society (ILTS), European Liver and Intestine Transplant Association (ELITA) and Liver Intensive Care Group of Europe (LICAGE)en_US
dc.titleImpact of Graft Type on the Survival Outcome of Salvage Liver Transplantation for Recurrent Hepatocellular Carcinomaen_US
dc.typeConference_Paperen_US
dc.identifier.emailChan, ACY: acchan@hku.hken_US
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hken_US
dc.identifier.emailChok, KSH: chok6275@hku.hken_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_US
dc.identifier.authorityChan, ACY=rp00310en_US
dc.identifier.authorityChan, SC=rp01568en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.identifier.hkuros229865en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats